As of 2026, UK private medical insurers generally do not cover GLP-1 weight-loss drugs such as Wegovy and Mounjaro, treating weight management as outside the acute-treatment model PMI is built on. Private users typically self-fund at roughly £120–£250/month. Pressure is building — including workplace pilots — but core cover hasn't moved yet.
- ✓UK insurers generally exclude GLP-1 weight-loss drugs from core cover in 2026.
- ✓Self-funders typically pay around £120–£250/month through private clinics and pharmacies.
- ✓Pressure is building via workplace pilots and wellness add-ons — but slowly.
The demand story, briefly
GLP-1 receptor agonists — semaglutide (Wegovy) and tirzepatide (Mounjaro) — have moved from diabetes clinics to the centre of British healthcare conversation in about three years. NHS access for weight loss exists but is tightly rationed through specialist services and a phased rollout, so the great majority of UK users pay privately through online clinics and pharmacies, typically around £120–£250 a month depending on drug and dose. Estimates put private users in the hundreds of thousands, growing steadily through 2026.
Which raises the obvious question for anyone with private medical insurance: if these drugs are clinically effective and privately prescribed, why isn't my insurer paying? It's now one of the most common questions brokers report hearing from customers and employers alike — and the answer says a lot about how UK health insurance is actually built.
Why insurers say no
The exclusion isn't arbitrary — it follows from how UK private medical insurance is built. Three structural reasons dominate:
- PMI covers acute, curable conditions. UK policies are designed around short, definable episodes — a diagnosis, a treatment, an end. Obesity management is long-term, and GLP-1s typically require ongoing use to maintain results; that puts them in the same excluded category as most chronic-condition medication.
- Outpatient drugs are largely out of scope anyway. Standard PMI generally covers drugs given in hospital as part of treatment, not repeat outpatient prescriptions — the same reason your blood-pressure tablets aren't covered.
- The actuarial problem. With obesity affecting roughly a quarter of UK adults, covering an open-ended £120–£250/month therapy could add enormous, hard-to-price cost to premiums for everyone. Insurers are wary of underwriting a benefit that a large share of members would immediately claim.
The pressure building on that position
The line is getting harder to hold. Employers increasingly ask about GLP-1 support in workplace health packages — some have piloted subsidised access through occupational health or wellness schemes, betting that weight-related health gains show up in absence and productivity. Some insurers and their wellness arms have edged in adjacently: weight-management programmes, digital coaching, discounted clinic partnerships — support around the drugs rather than the drugs themselves.
The direction of travel looks familiar from mental health a decade ago: excluded, then adjacent services, then partial cover as evidence and competitive pressure mounted. Whether GLP-1s follow that path depends on long-term outcome data, falling prices as competition and generics arrive, and whether a major insurer breaks ranks first. As of mid-2026, core PMI cover hasn't moved — but the adjacent offerings are multiplying.
Cover for everything else
What this means if you're weighing up cover
| Route | Typical 2026 position |
|---|---|
| NHS | Available for weight loss but tightly rationed; phased rollout via specialist services |
| Private self-pay | ~£120–£250/month via online clinics and pharmacies; most common route |
| Private medical insurance | Weight-loss drugs generally excluded; obesity-related conditions often covered normally |
| Workplace schemes | A few pilots and wellness subsidies; not standard |
If GLP-1 access is your main goal, buying PMI won't get you there in 2026 — budget for self-funding. If you want cover for everything else while you self-fund, that's a coherent combination many people run: a typical adult premium averages around £80/month, alongside a GLP-1 budget of £120–£250. Our weight-loss treatment cover guide tracks insurer positions in detail, and it's worth understanding a policy's exclusions before you buy — and talking to your GP or a regulated clinician before starting any medication.
Frequently asked questions
Do UK health insurers cover Wegovy or Mounjaro in 2026?
Generally, no. UK private medical insurers treat GLP-1 weight-loss drugs as outside core cover in 2026 — weight-management medication is a standard exclusion, and outpatient repeat prescriptions are largely out of scope for PMI anyway. Most private users self-fund at roughly £120–£250 a month.
Why do insurers exclude GLP-1 weight-loss drugs?
Three structural reasons: UK PMI covers acute, short-episode conditions rather than long-term management; outpatient drugs are generally excluded across the board; and with obesity affecting roughly a quarter of adults, an open-ended monthly therapy would be very hard to price without pushing up everyone's premiums.
Will health insurance cover GLP-1 drugs in future?
Possibly — pressure is building through employer demand, workplace pilots and insurer wellness programmes that sit adjacent to the drugs. The pattern resembles mental health cover's evolution: exclusion, then adjacent services, then partial cover. But as of mid-2026 no major UK insurer covers GLP-1s for weight loss on core PMI.
Are obesity-related conditions covered even if weight-loss drugs aren't?
Often, yes. Policies that exclude weight-loss medication and bariatric surgery frequently still cover acute obesity-linked conditions — joint problems, sleep apnoea investigations, cardiac care — on normal terms, subject to underwriting. Check the policy wording, because the boundaries differ between insurers.
How much do GLP-1 weight-loss drugs cost privately in the UK?
Typically around £120–£250 a month through regulated online clinics and pharmacies, depending on the drug and dose, usually including prescriber check-ins. Because insurers don't cover them in 2026, this is effectively the going rate for ongoing private use — factor it in as a standing cost, not a one-off.